Atracurium besylate is a non-depolarizing neuromuscular blocker used to facilitate endotracheal intubation and relax skeletal muscles during surgery. A non-depolarizing neuromuscular blocking agent with short duration of action.
- Mechanism
- Curator reviewed
Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
- Primary indication
- For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.Curator reviewed · 2 structured indications
- Formula / weight
- C65H82N2O18S2 · 1243.49 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1997
- Also known as
- Atracurium besilate · Atracurium dibesylate
- Code names
- BW-33A · Wellcome 33-A-74
Resolves to
XXZSQOVSEBAPGS-UHFFFAOYSA-LSMILES[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2What you can answer from here — as of September 23, 2026
Which drugs share a target with Atracurium besylate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account